Stock Research: Supernus Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Supernus Pharma

NasdaqGM:SUPN US8684591089
51
  • Value
    33
  • Growth
    67
  • Safety
    Safety
    100
  • Combined
    45
  • Sentiment
    53
  • 360° View
    360° View
    51
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. It operates in the biopharmaceutical industry with products like Qelbree, GOCOVRI, and Oxtellar XR. The company focuses on the treatment of CNS diseases. In the last fiscal year, the company had a market cap of $1,885 million, profits of $593 million, and revenue of $662 million, with 674 employees.

more
Index
Moonshot Tech
NASDAQ
D.J. US Pharmaceutical
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 18 29 37
Growth
67 51 49 77
Safety
Safety
100 100 75 96
Sentiment
53 66 32 80
360° View
360° View
51 73 32 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
78 23 48 57
Opinions Change
50 68 50 96
Pro Holdings
n/a 92 45 22
Market Pulse
71 43 33 56
Sentiment
53 66 32 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
33 18 29 37
Growth
67 51 49 77
Safety Safety
100 100 75 96
Combined
45 63 52 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
65 40 50 71
Price vs. Earnings (P/E)
41 32 37 64
Price vs. Book (P/B)
41 39 44 1
Dividend Yield
1 1 1 1
Value
33 18 29 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
78 10 43 51
Profit Growth
68 57 91 23
Capital Growth
25 48 29 97
Stock Returns
57 83 41 79
Growth
67 51 49 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 53 62
Refinancing
33 56 43 53
Liquidity
81 82 84 84
Safety Safety
100 100 75 96

Similar Stocks

Discover high‑ranked alternatives to Supernus Pharma and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: